$EVGN News

Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain

Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL

Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors

Evogene Reaches Agreement With Pure Capital Group To Resolve Differences

Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

Evogene Discloses That Another Nasdaq 180-Day Period For Regaining Minimum Bid Price Requirement Has Been Extended Until March 29, 2027

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Evogene (EVGN) Q2 2026 Earnings Call Transcript

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

Evogene Ltd. Q2 2026 Earnings Call Summary

Evogene Ltd (EVGN) (Q2 2026) Earnings Call Highlights: Strategic Pivot to AI-Driven Drug ...

Evogene Ltd. (EVGN) Q2 2026 Earnings Call Transcript

Evogene Reports Second Quarter and First Half 2026 Financial Results

CORRECTION: Evogene Q2 EPS $(0.13) Beats $(0.27) Estimate, Sales $347.000K Beat $325.000K Estimate

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Evogene Schedules Second Quarter 2026 Financial Results Release

Evogene and ELEO to develop new oral PCSK9 inhibitors

Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

Evogene's AgPlenus Subsidiary Introduces Antifungal Potency Predictor

EverGen Infrastructure Announces Record RNG Production for Q2 2026